Related Experiment Video
Updated: Sep 20, 2025
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
19.0K
Nonketotic Hyperglycinemia: Insight into Current Therapies
Magdalena Nowak1, Piotr Chuchra1, Justyna Paprocka2
1Students' Scientific Society, Department of Pediatric Neurology, Faculty of Medical Sciences in Katowice, Medical University of Silesia, 40-752 Katowice, Poland.
Journal of Clinical Medicine
|June 10, 2022
Summary
Nonketotic hyperglycinemia (NKH) is a rare metabolic disorder. Current treatments like sodium benzoate and NMDA receptor antagonists show variable effectiveness, necessitating further research into NKH therapies.
Area of Science:
- Biochemistry
- Genetics
- Neurology
Background:
- Nonketotic hyperglycinemia (NKH) is a rare inherited metabolic disorder.
- It involves glycine accumulation, particularly in the central nervous system (CNS).
- NKH presents in severe and attenuated forms with distinct clinical outcomes.
Purpose of the Study:
- To review the therapeutic potential, challenges, and effectiveness of current NKH treatments.
- To summarize existing knowledge on managing nonketotic hyperglycinemia.
- To highlight areas for future research in NKH therapy.
Main Methods:
- Literature review of existing studies on NKH.
- Analysis of therapeutic strategies including sodium benzoate and NMDA receptor antagonists.
- Synthesis of data on clinical outcomes and treatment effectiveness.
Main Results:
- Current therapies for NKH include sodium benzoate and NMDA receptor antagonists (dextromethorphan, ketamine).
- These treatments show variable effectiveness, leading to doubts about their overall efficacy.
- No causal treatment for NKH has been identified to date.
Conclusions:
- Therapeutic options for NKH are limited and their effectiveness is inconsistent.
- Further research is crucial to develop more effective treatments for nonketotic hyperglycinemia.
- Understanding the challenges and potential of current therapies is key to improving patient outcomes.
Related Concept Videos
01:15Diabetes: Management and Pharmacotherapy
415
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
415
01:24Glucagon-like Receptor Agonists
443
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
443
01:15Hypoglycemia and Glucagon
356
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
356
01:23Dipeptidyl Peptidase 4 Inhibitors
271
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
271
01:22Diabetes Mellitus: Overview and Type I Subtype
3.3K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
3.3K
01:20Inborn Errors of Metabolism
250
Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
250